Business Monitor International


Romania Pharmaceuticals & Healthcare Report

Published 14 November 2014

  • 112 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Romania Pharmaceuticals & Healthcare Report

News: Argentina registered the biggest two-day loss in its bonds since 2012 as the International Swaps & Derivatives  Association(ISDA)'s determinations committee ruled that the country's failure to pay interest will trigger credit default swaps of USD1bn. The ruling was issued by the committee after the government failed to meet a payment deadline on July 30 on USD539mn of notes. However, the country has declined the allegation and stated that it has already made the payment to the bond's trustee (Bloomberg).

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Romania Pharmaceutical Sales, Historical Data And Forecasts (2010-2018)
15
Healthcare Market Forecast
16
Table: Romania Healthcare Expenditure Trends, Historical Data And Forecasts (2010-2018)
18
Table: Romania Government Healthcare Expenditure Trends, Historical Data And Forecasts (2010-2018)
18
Table: Romania Private Healthcare Expenditure Trends, Historical Data And Forecasts (2010-2018)
18
Prescription Drug Market Forecast
19
Table: Romania Prescription Drug Market Indicators, Historical Data And Forecasts (2010-2018)
20
Patented Drug Market Forecast
21
Table: Romania Patented Drug Market Indicators, Historical Data And Forecasts (2010-2018)
22
Generic Medicine Market Forecast
23
Table: Romania Generic Drug Market Indicators, Historical Data And Forecasts (2010-2018)
24
OTC Medicine Market Forecast
25
Table: Romania Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Romania Pharmaceutical Trade Data And Forecasts (2012-2018)
28
Table: Romania Pharmaceutical Trade Data And Forecasts local currency (2012-2018)
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
32
Economic Analysis
32
Table: Economic Activity (Romania 2009-2018)
37
Industry Risk Reward Ratings
38
Central And Eastern Europe Risk/Reward Index
38
Romania Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
47
Industry Trends And Developments
48
Epidemiology
48
Healthcare System
49
Private Healthcare Provision
51
Healthcare Reform
52
Research And Development (R&D)
52
Clinical Trials
54
Medical Devices
54
Regulatory Development
56
Pharmaceutical Advertising
57
Intellectual Property Regime
57
Corruption
58
Pricing Regime
59
Reimbursement Regime
60
Latest Claw-Back Tax Developments
64
Competitive Landscape
66
Pharmaceutical Sector
66
Domestic Industry
66
Foreign Industry
66
Table: Members Of ARPIM, 2013
67
Pharmaceutical Company Developments
68
Pharmaceutical Wholesale
69
Pharmaceutical Retail
69
Company Profile
71
Actavis
71
Antibiotice Iasi
74
GlaxoSmithKline
77
Krka
80
LaborMed Pharma
82
Merck & Co
84
Novartis
86
Pfizer
88
Roche
90
Sanofi
92
Terapia Ranbaxy
94
Zentiva
97
Demographic Forecast
100
Table: Population Headline Indicators (Romania 1990-2025)
102
Table: Key Population Ratios (Romania 1990-2025)
102
Table: Urban/Rural Population & Life Expectancy (Romania 1990-2025)
103
Table: Population By Age Group (Romania 1990-2025)
103
Table: Population By Age Group % (Romania 1990-2025)
104
Glossary
105
Methodology
107
Pharmaceutical Expenditure Forecast Model
107
Healthcare Expenditure Forecast Model
107
Notes On Methodology
108
Risk/Reward Index Methodology
109
Index Overview
110
Table: Pharmaceutical Risk/Reward Index Indicators
110
Indicator Weightings
111

The Romania Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Romania Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Romania pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Romania, to test other views - a key input for successful budgeting and strategic business planning in the Romanian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Romanian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Romania.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc